News
BCLI
0.702
-11.10%
-0.088
Weekly Report: what happened at BCLI last week (0518-0522)?
Weekly Report · 9h ago
BrainStorm Cell Therapeutics raises $400,000 in private placement at $0.95/share
PUBT · 6d ago
*BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
Dow Jones · 6d ago
Press Release: BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
Dow Jones · 6d ago
Weekly Report: what happened at BCLI last week (0511-0515)?
Weekly Report · 05/18 09:38
BrainStorm Cell Therapeutics GAAP EPS of -$0.19 beats by $0.17
Seeking Alpha · 05/15 21:27
Brainstorm Cell Q1 EPS $(0.19) Beats $(0.36) Estimate
Benzinga · 05/15 20:12
Weekly Report: what happened at BCLI last week (0504-0508)?
Weekly Report · 05/11 09:37
Weekly Report: what happened at BCLI last week (0427-0501)?
Weekly Report · 05/04 09:36
Weekly Report: what happened at BCLI last week (0420-0424)?
Weekly Report · 04/27 09:37
Weekly Report: what happened at BCLI last week (0413-0417)?
Weekly Report · 04/20 09:36
Weekly Report: what happened at BCLI last week (0406-0410)?
Weekly Report · 04/13 09:37
Weekly Report: what happened at BCLI last week (0330-0403)?
Weekly Report · 04/06 09:37
Brainstorm Cell Q4 EPS $(0.20) Beats $(0.37) Estimate
Benzinga · 03/31 22:49
BrainStorm Cell Therapeutics GAAP EPS of -$1.11 beats by $0.50
Seeking Alpha · 03/31 20:31
BrainStorm FY25 net loss narrows to $10.3 million
Reuters · 03/31 20:03
BRAINSTORM CELL THERAPEUTICS ANNOUNCES FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Reuters · 03/31 20:01
Weekly Report: what happened at BCLI last week (0323-0327)?
Weekly Report · 03/30 09:37
Weekly Report: what happened at BCLI last week (0316-0320)?
Weekly Report · 03/23 09:35
Weekly Report: what happened at BCLI last week (0309-0313)?
Weekly Report · 03/16 09:35
More
Webull provides a variety of real-time BCLI stock news. You can receive the latest news about Brainstorm Cell Therapeutics I through multiple platforms. This information may help you make smarter investment decisions.
About BCLI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.